Cannabis Law Report
SEPTEMBER 13, 2021
(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood.
Cannabis Law Report
DECEMBER 23, 2021
billion by 2025. The market sizing section provides forecasts on the estimated sales of the three most lucrative cannabinoid pharmaceuticals – from 2021-2025 – including Epidiolex, Sativex and Dronabinol. Global surveys of cannabis users indicate that around 40% of users have some medical component to their usage.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Miss Marijuana
FEBRUARY 1, 2025
Clinical trials are currently underway, so keep an eye out for new findings. The post Medical Marijuana for Cancer Treatment: Complete Patient Guide (2025) appeared first on Miss Marijuana. The more we learn, the more we can better understand how to use cannabis effectively as part of cancer care.
Miss Marijuana
FEBRUARY 7, 2025
As of 2025 , the legal status of THC and CBD is still evolving. While more clinical trials are needed, THC has already been shown to help improve quality of life for those dealing with these conditions. It’s used for everything from stress relief to sleep support, and it’s available in many places without needing a prescription.
Cannabis Law Report
JUNE 25, 2021
billion in 2025 at a CAGR of 14%. EMA also regulates and supervises the drug quality, check for the intended use of the drug and whether the drug is meeting the requirement of clinical trial. The market is expected to reach $2.72 The skin cancer drugs market consists of sales of skin cancer drugs.
Cannabis Law Report
NOVEMBER 16, 2021
As cleared by the FDA, the primary endpoint of the Phase 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of tumor necrosis factor-alpha (TNF-?), tumor necrosis factor receptor I (TNFRI) and IL-6.
Cannabis Law Report
NOVEMBER 15, 2021
Although a limited number of CGTs are currently on the market, FDA officials predicted in 2019 that the agency will receive more than 200 investigational new drug applications per year for cell and gene therapies and that by 2025, it expects to have accelerated to 10 to 20 cell and gene therapy approvals per year 1.
Expert insights. Personalized for you.
40 
Let's personalize your content